The combinations of MM-121 and paclitaxel significantly inhibit tumor cell proliferation, reduce expression of Survivin, and induce apoptosis in vivo. Our data support further studies to explore the therapeutic potential of MM-121 in combination with paclitaxel in breast cancer patients with erbB2-overexpressing tumors. Here, BIRC5 is linked to breast cancer.